1629P Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) therapy in patients (pts) with prior Radium-223 (223Ra)
Rahbar, K., Sarfaty, M., Peer, A., Leibowitz, R., Eiber, M., la Fougère, C., Prasad, V., Fendler, W.P., Rassek, P., Hasa, E., Dittmann, H., Bundschuh, R.A., Pabst, K.M., Kurtinecz, M., Korn, M., Essler, M., Sartor, O.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
1392P Lutetium-177-prostate-specific membrane antigen therapy (177Lu-PSMA) in patients (Pts) with prior radium-223 (223Ra): Safety and effectiveness outcomes
Rahbar, K., Essler, M., Eiber, M., la Fougère, C., Prasad, V., Fendler, W.P., Rassek, P., Hasa, E., Dittmann, H., Bundschuh, R.A., Pabst, K.M., Kurtinecz, M., Schmall, A., Verholen, F., Sartor, O.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article